Cough in chronic obstructive pulmonary disease: Is it important and what are the effects of treatment?

Cough

Volumn 9, Issue 1, 2013, Pages

  Calverley, Peter M A ^a,b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bronchitis; Chronic Obstructive Pulmonary Disease; Cough; Mucus; Treatment

Indexed keywords

CIGARETTE SMOKE; FLUTICASONE PROPIONATE; PLACEBO; SALMETEROL;

ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HEALTH STATUS; HUMAN; MORTALITY; MUCUS; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING CESSATION;

EID: 84879230131     PISSN: None     EISSN: 17459974     Source Type: Journal    
DOI: 10.1186/1745-9974-9-17     Document Type: Review

References (25)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2012,
2. Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1(3):305-314. 2707150, 18046867.
3. Medical Research Council Committee on Research into Chronic Bronchitis Instructions for the use of the questionnaire on respiratory symptoms 1966, Devon, UK: W.J.Holman, Medical Research Council Committee on Research into Chronic Bronchitis.
4. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994, 309(6959):901-911.
5. Gamble E, Grootendorst DC, Hattotuwa K, O'Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegel C, Morell F, Pavord ID, Rabe KF, Jeffery PK, Barnes NC. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007, 30(3):467-471. 10.1183/09031936.00013006, 17504799.
6. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454. 10.1056/NEJMra0804752, 19494220.
7. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011, 12(18):18. 3040135, 21272339.
8. Reid L. Measurements of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 1960, 15:132-141. 10.1136/thx.15.2.132, 1018549, 14437095.
9. Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 2001, 120(1):258-270. 10.1378/chest.120.1.258, 11451847.
10. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax 2000, 55(0040-6376):643-649. 1745828, 10899239.
11. Blanc FX, Macedo P, Hew M, Chung KF. Capsaicin cough sensitivity in smokers with and without airflow obstruction. Respir Med 2009, 103(5):786-790. 10.1016/j.rmed.2008.11.010, 19136241.
12. Fletcher C, Peto R. The natural history of chronic airway obstruction. BMJ 1977, 1:1645-1648. 10.1136/bmj.1.6077.1645, 1607732, 871704.
13. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996, 153(5):1530-1535. 10.1164/ajrccm.153.5.8630597, 8630597.
14. Probst-Hensch NM, Curjuric I, Pierre-Olivier B, Ckermann-Liebrich U, Bettschart RW, Brandli O, Brutsche M, Burdet L, Gerbase MW, Knöpfli B, Künzli N, Pons MG, Schindler C, Tschopp JM, Rochat T, Russi EW. Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohort. Thorax 2010, 65(2):150-156. 10.1136/thx.2009.115063, 19996350.
15. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-european cross-sectional study. Eur Respir J 2011, 37(2):264-272. 10.1183/09031936.00051110, 21115606.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327. 10.1164/ajrccm/145.6.1321, 1595997.
17. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N. Properties of the COPD assessment test in a cross-sectional european study. Eur Respir J 2011, 38(1):29-35. 10.1183/09031936.00177210, 21565915.
18. Chavannes N, Schermer T, Akkermans R, Jacobs JE, van de GG, Bollen R, van Schayck O, Bottema B. Impact of spirometry on GPs' diagnostic differentiation and decision-making. Respir Med 2004, 98(11):1124-1130. 10.1016/j.rmed.2004.04.004, 15526814.
19. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF. Wedzicha JA; evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators, susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138. 10.1056/NEJMoa0909883, 20843247.
20. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009, 135(4):975-982. 10.1378/chest.08-2062, 19017866.
21. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value Health 2010,
22. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999, 106(4):410-416. 10.1016/S0002-9343(99)00056-X, 10225243.
23. Smith J, Owen E, Earis J, Woodcock A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006, 117(4):831-835. 10.1016/j.jaci.2005.09.055, 16630941.
24. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361(9356):449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
25. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374(9691):685-694. 10.1016/S0140-6736(09)61255-1, 19716960.